Fluorine-18 (F-18) stands as the cornerstone radionuclide in positron emission tomography, with its 109.8-minute half-life and favorable decay properties enabling high-resolution molecular imaging across oncology, neurology, and cardiology. At Protheragen, we transform complex radiochemistry into reliable, GMP-grade F-18 labeled compounds—bridging the gap between bench-scale discovery and clinical-grade radiopharmaceutical supply.
F-18 is produced primarily via cyclotron irradiation of enriched oxygen-18 water through the nuclear reaction ¹⁸O(p,n)¹⁸F, yielding no-carrier-added [¹⁸F]fluoride with specific activities exceeding 10² GBq/μmol. This nucleophilic form dominates modern radiochemistry due to its substantially higher specific activity compared with electrophilic [¹⁸F]F₂, which requires carrier fluorine-19 and achieves only 100–600 MBq/μmol. The physical characteristics of F-18—97% positron emission, 635 keV maximum endpoint energy, and a mean positron range below 0.3 mm in tissue—translate into exceptional spatial resolution on PET scanners, making it the radionuclide of choice for quantitative molecular imaging.
![Molecular schematic visualization of Al‑[18F]fluoride chemical positioning](https://www.radiopharmacro.com/wp-content/themes/radiopharmacro/img/4-15-f-18-radiolabeling-service-1.jpg)
Fig 1. Chemical positioning schematic of Al-[18F]fluoride method. (Archibald, Stephen J., et al., 2021)
The radiolabeling chemistry of F-18 has evolved far beyond the classical nucleophilic aliphatic substitution (SN2) and aromatic substitution (SNAr) pathways. Contemporary methodologies now encompass transition metal-mediated late-stage fluorination using palladium(IV) and nickel complexes, diaryliodonium salt precursors for electron-rich arenes, enzymatic fluorination with fluorinase enzymes in aqueous media, and bioorthogonal click-radiolabeling strategies. These advances have dramatically expanded the structural diversity of molecules amenable to F-18 incorporation—from small-molecule kinase inhibitors and receptor ligands to peptides, antibodies, and nanoparticle constructs—enabling targeted imaging of previously inaccessible biological targets.
Protheragen delivers end-to-end F-18 radiolabeling solutions that span the entire development continuum—from early-phase tracer design and in vitro radiochemical feasibility studies through fully automated GMP synthesis, comprehensive quality control, and regulatory-compliant documentation for IND-enabling and clinical trial supplies. Our integrated CRDMO platform combines specialized radiochemistry expertise with robust preclinical in vivo imaging capabilities and IIT clinical trial management, ensuring that your F-18 labeled compound progresses efficiently from concept to patient dosing.
Our F-18 radiolabeling workflow is engineered to maximize radiochemical yield, minimize synthesis time, and ensure full traceability from cyclotron target irradiation to final product release. Each project follows a structured pathway tailored to the molecular class, intended application, and regulatory pathway of the tracer.
1. Project Consultation & Feasibility Assessment
Our radiochemistry team evaluates your target molecule's structural features, identifies optimal labeling positions, and selects the most appropriate fluorination strategy—whether direct nucleophilic substitution, transition metal-mediated labeling, or prosthetic group conjugation—based on chemical compatibility and desired specific activity.
2. Precursor Design & Synthesis
We design and synthesize the non-radioactive precursor molecule with appropriate leaving groups (triflates, tosylates, mesylates, nitro groups, or iodonium salts), protecting groups, and purification handles. All precursors undergo full analytical characterization (NMR, MS, HPLC) and stability validation before advancing to radiosynthesis.
3. Cyclotron Production & [18F]Fluoride Isolation
F-18 is produced via proton bombardment of enriched [18O]water on our cyclotron systems. The aqueous [18F]fluoride is trapped on anion-exchange cartridges (QMA), eluted with low-basicity protocols to preserve base-sensitive scaffolds, and azeotropically dried with acetonitrile in the presence of Kryptofix 2.2.2 and potassium carbonate.
4. Radiosynthesis & Reaction Optimization
The dried [18F]fluoride is reacted with the precursor under optimized conditions—solvent, temperature, time, and counterion—using automated synthesis modules. Reaction progress is monitored by radio-TLC, and crude products are purified via semi-preparative HPLC or solid-phase extraction to achieve radiochemical purity >95%.
5. Formulation, Sterile Filtration & Vialing
The purified radiotracer is formulated in an appropriate vehicle (typically phosphate-buffered saline or ethanol/saline mixtures), adjusted to physiological pH and osmolality, and sterile-filtered through 0.22 μm membranes into sterile vials under aseptic conditions within a certified hot cell.
6. Quality Control & Batch Release
Every batch undergoes comprehensive QC testing including radiochemical purity (radio-HPLC), chemical purity (UV-HPLC), specific activity, pH, osmolality, sterility, and endotoxin levels. A Certificate of Analysis (CoA) is issued upon successful completion of all release criteria, with full batch documentation archived for regulatory inspection.
7. Preclinical / Clinical Distribution & Stability Monitoring
Released products are dispatched under temperature-controlled conditions with validated cold-chain logistics. For clinical supplies, we coordinate with nuclear medicine departments and radiopharmacies to ensure timely delivery within the tracer's usable shelf life, accompanied by administration protocols and radiation safety guidelines.
Ready to advance your F-18 radiopharmaceutical program? Whether you are exploring a novel tracer concept, seeking GMP-compliant clinical supplies, or planning an IIT clinical trial, our radiochemistry and clinical operations teams are prepared to support your vision. Reach out to us today to discuss your project requirements, and let Protheragen be the catalyst that transforms your radiochemical innovation into clinical reality.
Reference